Xtl Biopharmaceuticals (XTLB) Asset Utilization Ratio (2011 - 2024)

Xtl Biopharmaceuticals (XTLB) posted quarterly Asset Utilization Ratio of 0.25 for Q4 2024, up 392.22% on a QoQ basis from 0.05 in Q3 2018.

Xtl Biopharmaceuticals (XTLB) Asset Utilization Ratio (2011 - 2024) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported Asset Utilization Ratio for 7 consecutive years, with 0.25 the latest figure, recorded in Q4 2024.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.25 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.25 (changed N/A YoY) and the FY2025 annual result came in at 0.13, down 253.29% from the prior year.
Asset Utilization Ratio climbed to 0.25 in Q4 2024 per XTLB's latest filing, from 0.05 in the prior quarter.
Over the last five years, Asset Utilization Ratio for XTLB reached as high as 0.25 in Q4 2024 and fell as low as 0.25 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	66,801.52 Bn	66,801.23 Bn	-	-
2	Nanobiotix	1,916.61 Bn	1,916.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.65 Bn	466.85 Bn	1.35 Bn	0.69
5	Vertex Pharmaceuticals	121.94 Bn	114.69 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	69.85 Bn	61.09 Bn	3.31 Bn	0.37
7	Belite Bio	63.06 Bn	63.06 Bn	-	-
8	Argenx Se	55.74 Bn	50.56 Bn	1.41 Bn	-
9	Revolution Medicines	37.48 Bn	37.48 Bn	-	-
10	Xtl Biopharmaceuticals	2.58 Bn	2.58 Bn	-	-

Download Data